COT kinase inhibitors (Abbott)

N/A

Report date: 2025/03/18 20:00:05
NME

Base Information

Drug NameCOT kinase inhibitors (Abbott)
Drug Alias NameTPL-2 modulators (Abbott)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNuclear factor NF-kappa-B complex inhibitorsMitogen-activated protein kinase kinase kinase 8 inhibitors
TargetsNuclear factor NF-kappa-B complexMitogen-activated protein kinase kinase kinase 8
Therapy Area/IndicationsInflammation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAbbott Laboratories
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbbott Laboratories
Active IndicationsN/A
Inactive IndicationsInflammation

Other Information

ATC CodeN/A
Related LinksN/A